Objectives: To evaluate possible inconsistencies between recommended, actual and desired folate intake in European adult populations. Design: Review of dietary recommendations, of food consumption surveys, and of intervention and observational studies relating folate intake to the risk of neural tube defects and plasma homocysteine levels. Results: In Europe, mean dietary folate intake in adults is 291 mgad (range 197±326) for men and 247 mgad (range 168±320) for women. The recommended intakes vary between 200±300 mgad (men) and 170±300 mgad (women). However, women with a previous pregnancy affected by a neural tube defect (NTD), are recommended to take 4000 mgad of supplemental folic acid when planning a subsequent pregnancy. For those without a history of NTD, the use of 400 mgad of supplemental folic acid is the best option to prevent the occurrence of NTDs. A daily dose of 650 mg supplemental folic acid normalises elevated plasma homocysteine levels, which is a risk factor for cardiovascular diseases. A dietary folate intake of at least 350 mgad is desired to prevent an increase in plasma homocysteine levels of the adult population in general. Conclusions: Mean dietary folate intake in Europe is in line with recommendations, but the desired dietary intake of b350 mgad is only reached by a small part of studied European populations. It is considered unethical to investigate whether supplements with a dose lower than 400 mgad of folic acid are also protective against NTDs. However, research to establish the lowest effective dose of dietary folateasupplemental folic acid to optimise homocysteine levels and research on the bioavailability of folate is required. This will enable the choice of a strategy to achieve desired folate intakes in the general population. In the meantime, consumption of plant foods like vegetables, fruits, and cereals should be stimulated to reach the desired level of 350 mg of dietary folate per day.
Introduction
Folate is a B vitamin, which acts as a coenzyme in several single carbon transfer reactions to synthesise components of DNA, RNA, and proteins. The term folate describes the group of derivatives exhibiting the biological activity of the parent molecule pteroylmonoglutamic acid. In food, folate is mainly present as reduced tetrahydrofolate polyglutamate. Folic acid is the synthetic fully oxidised form of pteroylmonoglutamic acid, which is present in supplements and does not occur naturally in signi®cant quantities.
Folic acid is classically used to treat the megaloblastic anaemia arising during pregnancy or infancy, but which can also originate from a poor dietary intake or from absorption disorders like coeliac disease. Folic acid is never used to correct the macrocytic anaemia due to vitamin B 12 de®ciency (Passmore & Eastwood, 1986) . During the last 30 y new functions of folate have been discovered. There is now solid evidence that folic acid supplementation during the periconceptional period significantly reduces the risk of giving birth to a child with a neural tube defect (NTD) (MRC, 1991; Czeizel & Duda Âs, 1992) . More recent ®ndings indicate that supplementation with folic acid decreases plasma homocysteine levels (Brattstro Èm et al, 1988; Ubbink et al, 1993a Ubbink et al, , 1993b Ubbink et al, , 1994 . This a signi®cant ®nding, since elevated plasma homocysteine levels are found to be an independent risk factor for vascular diseases (Boushey et al, 1995) . Moreover, there are indications that a high dietary folate intake is associated with a reduced prevalence of NTDs and with lower plasma homocysteine levels (Yates et al, 1987; Bower & Stanley, 1989; Milunsky et al, 1989; Werler et al, 1993; Selhub et al, 1993; Friel et al, 1995; Shaw et al, 1995; Verhoef et al, 1996) . Finally, there is a growing number of studies which show that a high folate intake is related to a reduced risk of certain cancers, like colorectal cancer (Giovannuci et al, 1993) , but thus far no conclusive evidence on this relation is available (Mason, 1995) .
From a public health perspective these new insights in the role of folate are very important. Consequently, this has raised concern about the folate intake of the general population both by the scienti®c community Wald & Bower, 1994; Boushey et al, 1995) and health authorities (CDC, 1991; FNC, 1992b; EAG, 1992; DHHS/PHS, 1992; HC/FNC, 1993; FDA, 1994) Scientists have proposed to increase the current recommended intake levels for folate (Selhub et al, 1993; Jacob et al, 1994; O'Keefe et al, 1995; Verhoef et al, 1996) , which has resulted in a discussion on possible strategies to raise the folate intake of the general population (Wald & Bower, 1994; Picciano et al, 1994; McNulty, 1995; Boushey et al, 1995) .
This review explores possible discrepancies between what is recommended, what is consumed, and what is desired with regard to the prevention of NTDs (occurrent and recurrent) and normal plasma homocysteine levels. We concentrate on the general adult population (age 18±64 y), and have not included pregnant women. The neural tube closes in early pregnancy namely between the 24th and 28th day . At this moment, most women are not aware of the fact that they are pregnant, which requires an optimal folate intake already before conception. Therefore, women of childbearing age are considered instead of pregnant women.
Folate recommendations for adults
Recommended dietary intake (RDI) is a general term to describe the intake level estimated to be suf®cient to cover the needs of the majority (97.5%) of the healthy population. The recommendation should provide a margin of safety to allow for periods of decreased intake, increased utilisation, individual variability and bioavailability of natural food folates. The RDI can be used to evaluate intake ®gures derived from nutritional surveys, for example to detect groups with a low intake (Bailey, 1995) .
Within the European community, France, Germany, Italy, Ireland, The Netherlands, Portugal, Spain and the UK have their own set of RDIs. Belgium reports to use the recommendations of several countries (the USA, the UK, The Netherlands and France) and Greece uses those of the FAO/WHO and the USA. The Northern European countries Denmark, Sweden, Norway, and Iceland have established the Nordic Nutrition Recommendations. Beyond the European community, Bulgaria, the Czech and Slovak republic, Finland, Hungary, Poland and Russia all have their own recommendations (Truswell et al, 1983) .
The most up to date recommendations for dietary folate intake in Europe are those of France, Germany, The Netherlands, and the UK. These recommendations, and those of the FAO/WHO and the USA are summarised in Table 1 . The recommendations for males vary from 200± 300 mg/d and for females from 170±300 mg/d. Despite this variation between countries, the most frequently recommended level of dietary folate intake is 200 mg/d for men and women.
The variation in recommended intake levels is due to the fact that each country has its own approach, correction factors, and publications on which the recommendations are based. In general, two manners to establish the RDI for folate can be distinguished. One approach is to determine a minimum requirement which is necessary to maintain normal metabolic processes or to cure clinical and biochemical symptoms of folate de®ciency in patients and healthy persons. This minimum amount is then increased in order to correct for bioavailability and individual variation. Another method is to evaluate the average dietary folate intake of a population with a known biochemical folate status. For example, with information on the folate intake and the percentage of the population having low red blood cell folate values, an RDI value can be estimated which can assure a suf®cient folate intake for all persons in this population. The committees which constituted the RDI for the FAO/WHO, the USA, the UK, and France combined both approaches. The RDIs of The Netherlands and Germany were solely based on the ®rst approach. The estimated minimum requirements, the correction factors, and the publications on which the recommendations are based, are given in Table 1 .
Folate intake in adults
Folate is present in a wide range of foods. Particularly rich in folate are liver, yeast, green leafy vegetables, legumes, and fruits like clementines and grapefruits (Holland et al, 1991) . These foods are not necessarily the predominant contributors to the folate intake. Major contributors to the folate intake in The Netherlands, the UK, and Ireland are vegetables, bread and potatoes, responsible for respectively 15±22%, 12±22%, and 10±15% of the total daily intake (Bausch-Goldbohm et al, 1995; Lee & Cunningham, 1990) . Folate intakes of adult populations in Europe are shown in Table 2 . The age categories are tabulated in the format they were shown by the original survey. This means that for some countries the folate intake of subjects under 18 y are presented as well. For this table large recent national and regional nutrition surveys have been used. When more than one survey per country was available, the most representative study is shown.
The highest folate intake was reported in the Parisian area in France, namely median folate intake of men was higher than 400 mg/d, and of women higher than 350 mg/d (Hercberg et al, 1993) . The lowest folate intakes were found in British, Swedish, and Irish females, and in Irish men aged 40 y and older, namely in these populations the median or mean folate intakes were lower than 200 mg/d Becker 1992; Lee & Cunningham, 1990) . Overall, the weighed mean folate intake was 291 mg/d (range: 197±326 mg/d) for men and 247 mg/d (range: 168±320 mg/d) for women.
Differences in folate intake may partly re¯ect differences in dietary habits among the European countries. For example, the higher folate intake in France, but also in Spain and Portugal, might originate from the Mediterranean diet consumed in these populations. Compared to North European diets, this diet consists of a higher portion of folate-rich foods such as vegetables, fruits, and whole grains (Kushi et al, 1995) .
Methodological differences between studies are another source of variation in folate intake. The several methods used to collect dietary information all have their own advantages and disadvantages which can potentially have led to an over-or underestimation of the habitual intake (McNulty, 1995) . An important problem with estimating the folate intake, is the lack and the unreliability of the folate content data in food composition tables. This problem can lead to an underestimation of the actual folate intake (Black et al, 1985) . Most nutrition surveys did not use standardised internationally accepted food composition tables, but tables based on foods commonly eaten within that country. An exception is the Dutch survey, in which the most recent edition of the McCance and Widdowson's was used (Holland et al, 1991) . This food composition table is very useful since it gives a complete overview of the folate content of a broad range of foods and all food samples have been analysed using the same method.
The analysis of the folate content of food is known to be dif®cult. The principal forms of folate in food are reduced pteroylpolyglutamates. These folates can be measured by high-performance liquid chromatography (HPLC), ligand binding methods, or microbiological assays, generally with Lactobacillus casei . The accuracy of the analysis is highly dependent on the preparative steps, consisting of the enzymatic deconjugation and the extraction of the polyglutamates . Some previously used extraction techniques might not have yielded a complete extraction of folate from the food sample matrix . Developments in determining folate content, indicate that part of the published data may have underestimated the folate content of foods. The improvement of methods to analyse the folate content of foods, might in the future lead to a more reliable estimation of the folate intake. We assumed that the nutritional surveys, cited in this review, coped with fairly similar unreliability of the analytical data, therefore we still consider it appropriate to compare intake data between the studies.
Methodological factors like the in-or exclusion of vitamin supplements or whether corrections were made for products forti®ed with folic acid, do not seem to explain differences in folate intake among countries. For instance, although foods forti®ed with folic acid and vitamin preparations were included in the intake values of the Irish survey, folate intake was low (Lee & Cunningham, 1990) . In contrast, the intake of folate was much higher in France excluding vitamin supplements and forti®ed products (except for some special formulas like dietetic products) (Hercberg et al, 1993) .
Developments regarding folate requirements:
what is the desired intake? Hibbard & Smithells (1965) were the ®rst who postulated that folate is involved in the closure of the neural tube, and even until now, the exact mechanism by which folate exerts its protection is not known. There are, however, some possible biochemical explanations. Folate is the substrate donor in the remethylation of homocysteine into methionine (Finkelstein, 1990) . A lack of folate will increase the levels of homocysteine and decrease methionine levels. Methionine is an essential amino acid and decreased levels might disturb the development of the neural tube (Coelho et al, 1989) . A disturbance in the metabolism of homocysteine could thus be the underlying factor in some NTDs cases (Steegers-Theunissen et al, 1991) . Indeed, it has been found that homocysteine levels were higher in a sub-group of women who previously gave birth to a child with an NTD, compared to normal controls (Steegers-Theunissen et al, 1994; Mills et al, 1995) . High homocysteine levels are also Folate intake in Europe A de Bree et al associated with vascular diseases (Boushey et al, 1995) . In this association homocysteine itself presumably plays a role in the vascular occlusion (Green & Jacobsen, 1995) . Because of the function of folate in the metabolism of homocysteine, folate may have the potential to prevent atherosclerosis and thrombosis as well. This hypothesis is supported by the results of observational studies, in which was found that low serum folate levels were associated with an increased risk of ischemic stroke (Giles et al, 1995) and coronary heart disease (Morrison et al, 1996) . Randomised trials in which the effect of an increased folate intake on the incidence of vascular diseases is studied, are needed to provide the direct proof for this association (Stampfer & Rimm, 1996) .
To give an indication of the amount of folate necessary to prevent NTDs we have summarised the available intervention trials (Table 3a) and observational studies (with N b 100 subjects) (Table 3b ), relating the folic acid/folate intake to the prevalence of NTDs. Women who gave birth to a child affected with an NTD are at recurrent risk, women without this medical history are at occurrent risk. The majority ( $ 95%) of all NTD cases are occurrences (Czeizel & Duda Âs, 1992) . The desired folate intake to obtain and maintain normal plasma homocysteine levels is estimated from the available results with apparently healthy subjects participating in intervention trials (Table  4a ) and in metabolic-studies (Table 4b) .
Desired folate intake with respect to the prevention of neural tube defects Scienti®c evidence. The ®rst intervention trial with women at recurrent risk was published in 1981. It was shown that the prevalence of NTDs in the group supplemented with folic acid (4000 mg/d) was signi®cantly lower compared to the prevalence in the non-supplemented group (Laurence et al, 1981) . However, the study population was small and non-compliers in the intervention group was transferred to the placebo group, which may have introduced some bias. Conclusive evidence was provided by the randomised double-blind trial of the MRC study (1991), which found a risk reduction of 72% for recurrent NTDs in the group of women periconceptionally supplemented with folic acid. The Hungarian trial of Czeizel and Duda Âs (1992) showed that the use of supplemental folic acid (800 mg/d) in the periconceptional period also results in a signi®cant risk reduction of the ®rst occurrence of NTDs. Two intervention trials (Table 3a) did, however, not show a signi®cant reduction in the prevalence of recurrent NTDs. This could either be due to the small number of cases or the non-randomised study design (Vergel et al, 1990; Kirke et al, 1992) .
The most reliable observational study design, namely a prospective cohort study, was provided by Milunsky et al, (1989) . All women were questioned about their use of supplements during a-fetoprotein or amniocentesis screening (around the 16th week of pregnancy). At that moment the women were not aware of the pregnancy outcome, which will have minimised the chance of recall bias and selective participation. The outcome of the study indicated that the use of folic acid supplements in the three months before and after conception reduced the risk of a child with an NTD by 64%. Furthermore, this study showed that starting the use of vitamin supplements after conception (in the ®rst 6 weeks of pregnancy) also had a protective effect: a risk reduction of 68%. The protective effect of folic acid supplementation has been con®rmed in casecontrol studies (Table 3b) (Mulinare et al, 1988; Bower & Stanley, 1989; Werler et al, 1993; Shaw et al, 1995) .
In two case-control studies the reduction in the risk of an NTD-affected birth was not signi®cant (Winship et al, 1984; Mills et al, 1989) . The study of Winship et al, (1984) lacked information on the use of non-prescribed drugs (of which folic acid is a common one) and on the use of drugs prescribed by hospital physicians. The zero ®nding in the study of Mills et al. (1989) may be caused by the low prevalence of NTDs in the geographic area. NTDs in such areas probably have a genetic basis or originates from other causes than a lack of folic acid . Furthermore, women who started the use of supplements after conception seem to be classi®ed as`non-users' (Mills et al, 1989) , whereas other observational studies have indicated that folic acid can also be protective in this period (Milunsky et al, 1989; Bower & Stanley, 1989; Shaw et al, 1995) . Other reasons could be the broad range of central nervous system defects that were included as cases in both studies (Winship et al, 1984; Mills et al, 1989) .
Desired level of folate intake: recurrent NTDs. In intervention trials studying the effect of supplemental folic acid on the recurrent risk of NTDs, the doses varied from 360± 5000 mg/d. the study of Smithells et al, (1983) showed the highest risk reduction (86%), while they used the lowest dose of folic acid (360 mg/d). However, this was a nonrandomised trial and certain characteristics of the study population, like genetic predisposition, might have added to the highly signi®cant risk reduction. In the reliable MRC study 4000 mg of folic acid was supplied daily (MRC, 1991) . The USA Centers for Disease Control and Prevention were the ®rst to react on this de®nitive proof that folic acid supplementation can prevent recurrent NTDs. In August 1991 they advised all women with a history of an NTD pregnancy to take 4000 mg supplemental folic acid per day during the periconceptional period (CDC, 1991) . Somewhat later the health authorities in The Netherlands and the UK formulated comparable recommendations (4000±5000 mg/d of supplemental folic acid) to reduce the recurrent risk of NTDs (FNC, 1992b; EAG, 1992) . We support the advice that women who previously have had a child affected by an NTD should take 4000 mg of supplemental folic acid per day during the periconceptional period to prevent recurrence. Toxic side effects of folic acid, even in very large doses (15±60 mg/d), have not been described for healthy people. However, the use of supplements in doses above 1000 mg/d might complicate the diagnosis of a vitamin B 12 de®ciency and, in case of epilepsy, it might induce seizure activity in drug-controlled subjects (Butterworth & Tamura, 1989; Dickinson, 1995) . Because of these potential side-effects, folic acid supplements in doses of 4000±5000 mg/d and higher are only prescribed under medical supervision.
Desired level of folate intake: occurrent NTDs. The Hungarian intervention trial (Czeizel & Duda Âs, 1992) provided women with daily supplements containing 800 mg folic acid. The supplements used in the observational studies provided between 0±1000 mg of folic acid and were taken at a frequency ranging from`once a week' to`daily'. The most distinct indication of the lowest necessary dose to establish the protective effect is provided by Werler et al (1993) . In this study 400 mg/d of folic acid (during 1 month Folate intake in Europe A de Bree et al 
CI con®dence interval
Folate intake in Europe A de Bree et al Table 4a Intervention studies on the effect of folic acid intake and total plasma homocysteine (tHcy) levels in apparently healthy adults (n 6) or 370 (n 6) mg levels supplemental folic acid per day.
Final mean serum folate was signi®cantly lower in women fed on Small intervention groups, only women.
Duration 70 days.
the 200 and 300 mg total folate diet, compared to the women on the 400 mg diet (6.4, 7.3 and 14.3 nmol/L respectively, P 0.003).
There were no signi®cant differences in ®nal mean red cell folate between the three groups, although low values (`263 nmol/L) were more frequently seen in the subjects on the 200 mg/d diet The ®nal tHcy levels were signi®cantly higher in the 200 mg/d group compared to the 300 and 400 mg/d groups (12.6, 8.4 and 7.7 P`0.05)
Folate intake in Europe A de Bree et al 655 before and after the last menstrual period) signi®cantly reduced the risk of a ®rst NTD-affected pregnancy by 70%. Shaw et al (1995) found a signi®cant reduction of 46% with a daily dose between 400±900 mg in the three months after conception. In a random sample (n 150) of the cohort of Milunsky et al (1989) , in which relative risks between 0.29±0.36 were found, 45% of the women used supplements providing 1000 mg folic acid per day and another 45% used supplements containing 300±400 mg folic acid per day. In observational studies the risk reductions for women with a high dietary folate intake compared to those with a low dietary intake, are small (30±40%) and often nonsigni®cant (Milunsky et al, 1989; Werler et al, 1993; Shaw et al, 1995) . Only Werler et al (1993) found a signi®cant risk reduction of 40% for an NTD-affected pregnancy with a dietary folate intake between 311±391 mg/d (fourth quintile, not shown in Table 3b ) compared to the lowest quintile of intake (31±196 mg/d), and a dose related decline in risk according to the quintiles of dietary folate intake (P for trend 0.02).
In case-control studies using total folate intake, it is not always clear whether the protective effect is due to food folates or to folic acid of supplements. Shaw et al (1995) found that total folate intake at a level of more than 1000 mg/d signi®cantly reduced the occurrent NTD risk by 61%. As an intake of 1000 mg/d is dif®cult to reach without the use of supplements, folic acid and not dietary folate was probably responsible for the protection. Bower & Stanley (1989) found signi®cant risk reductions (69± 84%) with high intake of`free' folate (folates with a short glutamic chain, which can be measured microbilogically without pre-treatment with a deconjugase), whereas high intake of total folate did not result in a signi®cant protection. The authors gave two possible explanations for their ®ndings: (1) conjugated folate is less well absorbed compared to free folate, or (2) conjugated folate in the used food composition tables were underestimated. However, it seems more likely that the high free folate intake indicates the use of folic acid preparations, which probably accounted for the protection against NTDs. In addition, it has to be remarked that the concept of`free' folate is a vague concept, since its measurement is unreliable (Tamura et al, 1972a; Tamura et al, 1972b) .
As a result of the insights in the prevention of occurrent NTDs, the Department of Health and Human Services/ Public Health Service in the USA and the Dutch Health Council/Food and Nutrition Council published follow-up reports in which all women of childbearing age are advised to assure that their daily total folate intake (of natural sources, forti®ed foods, or supplements) is 400 mg (HC/ FNC, 1993; DHHS/PHS, 1992). The Dutch advice speci®-cally mentions women at increased risk of an NTD-affected pregnancy as a result of their medical history, for example the use of anti-epileptic drugs, diabetes mellitus, or hormone treatment to induce ovulation. These women are advised to take a daily vitamin preparation containing 400 mg folic acid besides their normal diet, during the periconceptional period (HC/FNC, 1993) . The advice to supplement the daily diet with an extra 400 mg folate (either from natural sources, forti®ed foods, or supplements) was given to all women who are planning a pregnancy by the Expert Advisory Group in the UK (EAG, 1992) . We are of opinion that the scienti®c evidence presented here, is in agreement with the advise to use a daily supplement providing 400 mg folic acid, for women planning a pregnancy without a history of NTDs.
Desired folate intake with respect to normal plasma homocysteine levels Scienti®c evidence. There is no consensus considering the de®nition of normal or elevated plasma homocysteine levels. Reported normal plasma values in healthy blood donors ranged from 7.9±9.3 mmol/L (Green & Jacobsen, 1995) . Values b16.3 mmol/L are commonly considered indicative of milk hyperhomocysteinemia (Ubbink et al, 1993a (Ubbink et al, , 1993b (Ubbink et al, , 1994 , although others have used levels b13.6 mmol/L (Hall & Chu, 1990) , b14 mmol/L (Selhub et al, 1993) , and b15 mmol/L (Genest et al, 1991) .
One of the ®rst intervention trials (Table 4a ) in which the effect of folic acid supplementation on plasma levels of homocysteine was investigated, was performed in 1988. The authors showed that daily supplementation with 5000 mg folic acid signi®cantly reduced homocysteine levels with 52% in a group of men and women with slightly elevated baseline values. This reduction was not observed in the group supplemented with vitamin B 6 or B 12 . Unfortunately, this study did not include a placebo group (Brattstro Èm et al, 1988) . Using a daily combined vitamin supplement containing 1000 mg folic acid, 12.2 mg vitamin B 6 , and 0.4 mg vitamin B 12 for six weeks in mild hyperhomocysteinemic men, demonstrated that high plasma homocysteine levels can be normalised. Doubling the vitamin doses for two weeks did not result in a further decrease in homocysteine levels (Ubbink et al, 1993a) . Using the combined supplement (1000 mg folic acid, 12.2 mg vitamin B 6 , and 0.4 mg vitamin B 12 ), Ubbink and co-workers showed that some mild hyperhomocysteinemic men require only temporary vitamin supplementation to obtain long-term normal plasma homocysteine levels: after 6 weeks of vitamin intervention the advice to include more folate-rich foods in the diet was suf®cient to maintain normal plasma homocysteine levels (`16.3 mmol/L) for at least 48 weeks. Adherence to the dietary guidelines should have provided 200 mg folate per day (Ubbink et al, 1993b) . Ubbink et al (1994) also designed a placebo-controlled trial in which the individual effects of vitamin B 6 (12.2 mg), B 12 (0.4 mg) and folic acid (650 mg) on mild hyperhomocysteinemia were compared with the effects of a combined supplement and a placebo. No signi®cant reduction in mean plasma homocysteine level was found in the placebo group nor in the vitamin B 6 group. In contrast, the groups supplemented with vitamin B 12 , folic acid and the three vitamins combined showed reductions of respectively 15, 42 and 50%. The reduction in mean homocysteine level with the combined supplement did not signi®cantly differ from the reduction established with folic acid alone. From these results the researchers concluded that the homocysteine-lowering effect of the combined supplement was mainly due to folic acid. Table 4b shows two studies in which plasma homocysteine levels were used as an index of`functional' folate de®ciency in healthy subjects. Jacob et al (1994) performed a controlled depletion/repletion/depletion/repletion study for 108 d. During the depletion periods the subjects were fed a diet providing $ 25 mg/d of dietary folate. Homocysteine levels increased signi®cantly during depletion and did not normalise in the repletion phases, when the participants were provided daily with 74 mg supplemental folic acid and 25 mg dietary folate. As they assumed that 74 mg folic acid equals 148 mg dietary folate (bio-availability of 50%), the total folate intake of 173 mg/d was only slightly less than the USA RDA of 200 mg/d (Table 1) . Based on the lack of normalisation of the homocysteine levels during the repletion periods, the authors concluded that the RDA does not provide a suf®cient margin of safety. This conclusion is supported by the results of a controlled dietary trial of O' Keefe et al (1995) . For a period of 70 d, a daily diet providing 30 mg dietary folate plus 170 mg supplemental folic acid, signi®cantly increased plasma homocysteine levels as compared to baseline. Homocysteine levels remained normal in the groups with a daily intake of 30 mg dietary folate plus respectively 270 and 370 mg of supplemental folic acid.
Desired levels of folate intake: normal plasma homocysteine levels. The lowest dose of folic acid found to effectively decrease elevated homocysteine levels (b16.3 mmol/ L) is 650 mg/d (Ubbink et al, 1994) . There is, however, no reason to assume that lower doses of folic acid would not be effective. In fact, preliminary results of Dierkes (1995) and Den Heijer et al (1995) showed that folic acid supplements in respective doses of 400 and 500 mg/d, signi®cantly reduced homocysteine levels in subjects with homocysteine levels considered normal (`16.3 mmol/L). This seems to indicate that levels commonly considered`normal' (`16.3 mmol/L) might not be optimal. Indeed, accumulating evidence indicates a dose-response relationship between plasma homocysteine levels and the risk of cardiovascular disease (Taylor et al, 1991; Arnesen et al, 1995; Perry et al, 1995; Verhoef et al, 1996) . Future research needs to focus on describing the shape of this doseresponse curve in order to determine an optimal plasma homocysteine level or range.
There is some evidence that 200 mg/d dietary folate is suf®cient to maintain`normal' homocysteine levels after normalisation with vitamin supplements (Ubbink et al, 1993b) , which is in contrast with the results of the depletion study of Jacob et al (1994) and the balance study of O' Keefe et al (1995) . From these studies it is dif®cult to estimate a desirable folate intake in light of`normal' plasma homocysteine levels, since no control groups were included and only a small number of subjects were investigated (Ubbink et al, 1993b; Jacob et al, 1994; O'Keefe et al, 1995) . Therefore, it seems safer to rely on the more credible results found with a daily supplement of 650 mg folic acid (Ubbink et al, 1994) . On the other hand, observational studies in which the folate intake was plotted against plasma homocysteine levels, found that homocysteine levels reached its nadir at total folate intakes of 350± 400 mg/d and higher (Selhub et al, 1993; Verhoef et al, 1996) . These studies investigated total folate intake, namely from the diet and supplements, but when food folates were plotted against plasma homocysteine levels, the same amount of folate accounted for the plasma homocysteine nadir (P Verhoef, unpublished data). Consequently, we cautiously consider a dietary folate intake of at least 350 mg/d a desired intake to maintain`normal' homocysteine levels. For the reduction of initial high homocysteine levels, extra supplemental folic acid in a dose of 650 mg/d might be necessary.
Discussion
Comparison of recommended, actual, and desired levels of folate intake Most health authorities recommend a daily intake of 200 mg dietary folate for both men and women (Table 1) . Nutrition surveys which give information on mean folate intake and the standard deviations, offer the possibility to estimate the proportion of the population with an intake below the generally recommended level of 200 mg/d. However, this is only allowed when folate intake is normally distributed, which appeared not to be the case evaluating medians and percentile ®gures. Nevertheless, it is still possible to make comparisons based on common sense. For example, when median folate intake of a population equals the RDI, 50% of the population has an intake below the RDI. Using this strategy, Table 2 indicates that the majority of the adults in the studied European countries meet the average RDI of 200 mg/d; weighed mean intake is 291 mg/d for men and 247 mg/d for women and median values lower than 200 mg/d are not frequently seen.
There appears to be a North±South gradient in dietary folate intake as the highest folate intake is observed in the Mediterranean area, and the lowest intakes are found in the UK, Sweden, and Ireland. In the latter countries a substantial part of the population does not meet the average recommended folate intake of 200 mg/d, which could indicate that the folate requirements for some individuals are not completely covered. However, it remains possible that the folate intake is underestimated due to unreliable food composition tables (Black et al, 1985; Gregory III et al, 1990; .
Comparison of actual intakes with the recommended intakes cannot be used to diagnose under-, mal-or overnutrition of groups or individuals. This can only be done after the assessment of the clinical or biochemical status (Truswell et al, 1983) . The folate status can be determined by measuring the concentration of folate either in plasma or serum (re¯ecting recent folate intake), in the red blood cells (re¯ecting intake of the past 2±3 months), or by measuring fasting total plasma homocysteine levels (Sauberlich, 1995) . Herbeth et al (1985) calculated the percentage of a population (n 710) with sub-normal folate intake, namelỳ 200 mg/d, whose biochemical result was also sub-normal (plasma folate`5 mg/L or red blood cell folate`200 mg/ L). These positive predictive values for men and women, for plasma and red blood cell folate levels, were low (men: plasma 23.2%; red blood cell 16.7%; women: 24.9%; 20.5%). This demonstrates that although the folate intake in a sub-group was lower than the RDI, the folate status of the majority (b75%) of this sub-group was normal. This is in line with the safety margins with which the RDI is established.
Four levels of desired folate intake can be distinguished: (1) 4000 mg/d of supplemental folic acid for women with a history of an NTD-affected pregnancy to prevent the recurrence of NTDs; (2) 400 mg/d of supplemental folic acid for women planning a pregnancy to prevent the occurrence of NTDs; (3) 650 mg/d of supplemental folic acid for adults with elevated plasma homocysteine levels; and (4) a total dietary folate intake of at least 350 mg/d for the general adult population to maintain`normal' plasma homocysteine levels.
For women who want to conceive, there is solid evidence to support the desired intakes to lower recurrent and occurrent NTD risk. Given this evidence it is unethical to dedicate more research to determine the lowest preventive dose. Intakes of 4000 mg/d can only be achieved by the use of folic acid supplements. For example, a simulation study of Bausch-Goldbohm et al (1995) indicated that less than 1% of the studied women of childbearing age (n 1725) reached a folate intake b1000 mg/d when forti®ed bread and bread substitutes were included in the habitual diet (forti®cation level: 300 mg folic acid/100 g product). At present the use of folic acid supplements also appears to be the best option preventing the occurrence of NTDs. The reason for this is, that a high dietary folate intake did show a much lower (and often not signi®cant) risk reduction compared to the risk reduction obtained with folic acid supplements ( $ 30% vs $ 70%: Table 3a and 3b). In addition, at present we are not capable to calculate the dietary equivalent of 400 mg of supplemental folic acid due to scarce data on the bioavailability of folate.
The data to establish a desirable folate intake with regard to`normal' plasma homocysteine levels, are less numerous and less conclusive compared to the data for the prevention of NTDs. Until new data demonstrate that plasma levels of homocysteine can be lowered with small doses of supplemental folic acid or with dietary folate, it seems not feasible to realise an extra folate intake, equally effective as 650 mg of folic acid, with the diet alone. The diet needs to be supplemented with folic acid preparations or foods forti®ed with folic acid. To maintain`normal' plasma homocysteine levels, food folates alone seem to be effective (Selhub et al, 1993; Verhoef et al, 1996) . Table 2 indicates that a small part of the European population reached this desired dietary folate intake of at least 350 mg/d. In France, the majority of the studied population has a habitual dietary folate intake above 350 mg/d (median intake men $ 410 mg/d, women $ 370 mg/d) (Hercberg et al, 1993) . We have to bear in mind, however, that the evidence for maintaining`normal' plasma homocysteine levels with dietary folate, was derived from only two observational studies (Selhub et al, 1993; Verhoef et al, 1996) . Future results from randomised intervention trials might be able to provide more de®nitive answers considering the lowest effective dose of supplemental folic acid or dietary folate (from natural sources or forti®ed products) to lower and maintain`normal' plasma homocysteine levels.
As mentioned earlier, the knowledge on the bioavailability of food folates is limited. It is, however, known that the bioavailability of naturally occurring folate is lower than that of folic acid in supplements (Gregory III, 1989) . Sauberlich et al (1987) estimated that food folates are available for 50% relative to folic acid. This difference in bioavailability is largely due to the fact that folic acid (pteroylmonoglutamic acid) can be absorbed directly, whereas food folates (mainly polyglutamyls) need to be enzymatically hydrolysed to the monoglutamyl form before absorption . Although folic acid is highly available to the body, fortifying reduces the bioavailability due to characteristics of the carrier food, food matrix, food components which inhibit absorption, etc. For example, compared to folic acid, the bioavailability of forti®ed bread was 30%, of forti®ed maize 50%, and of forti®ed rice 60% (Colman, 1982) . However, despite this incomplete bioavailability, the folic acid bioavailability of forti®ed products seems higher than the bioavailability of folates naturally present in foods. As indicated by preliminary results of a three months intervention trial performed by Cuskelly et al (1996) . The average additional intake of women supplied with forti®ed foods namely bread and breakfast cereals (221 AE 95 mg/d of folic acid) was comparable to the average extra intake of women supplied with natural folate-rich sources (201 AE 117 mg/d of dietary folate). However, red blood cell folate only signi®-cantly increased in the women who consumed the forti®ed foods. Weaknesses of this study were that the design did not allow control of the dietary intake and of food preparation methods. In addition, the intervention groups were very small (Cuskelly et al, 1996) . Consequently, more data on bioavailability of folate in foods is needed.
Conclusions
Current dietary folate intake of adults (291 mg/d for men and 247 mg/d for women) is in line with the average recommended level, namely 200 mg/d. The desired daily intakes to prevent the recurrence or the occurrence of NTDs are respectively 4000 mg and 400 mg of supplemental folic acid. This ensures a higher effectiveness that dietary folate. Elevated plasma homocysteine levels can be`normalised' with 650 mg supplemental folic acid per day. To maintaiǹ normal' plasma homocysteine levels a dietary folate intake of at least 350 mg/d may be suf®cient.
None of the most recent recommendations for folate intake of the general adult population (Table 1) reaches the desired dietary folate intake level of 350 mg/d. Therefore, a reconsideration of the current recommendations for folate seems appropriate. Moreover, the dietary surveys (Table 2) show that only in the French population more than 50% of the population reaches a dietary folate intake b350 mg/d.
More research should be focused on the lowest effective dose of dietary folate/supplemental folic acid to stabilise/`normalise' plasma homocysteine levels. In addition, more data is needed on the bioavailability of folate either naturally or arti®cially present in foods. This research will enable the choice of the optimal strategy to achieve desired folate intakes in the general population. In the meantime, it will be worthwhile to stimulate the consumption of foods naturally rich in folate, especially in countries like the UK, Sweden, and Ireland where the folate intake is lower than 200 mg/d for more than 50% of some sub-groups, namely females, men ! 40 y. Increasing the consumption of foods of plant origin is safe and will increase the intake of other bene®cial nutrients simultaneously.
